# How SURMOUNT-MAINTAIN tested weight maintenance

- Article ID: research-161
- Product: GLP-2 TIRZ (glp-2-tirz-691, glp-2-tirz-714)
- Canonical page: https://heritagebiolabs.com/research-library/articles/161-how-surmount-maintain-tested-weight-maintenance
- Product collection: https://heritagebiolabs.com/research-library/products/glp-2-tirz
- Product page: https://heritagebiolabs.com/product/glp-2-tirz-691
- Product page: https://heritagebiolabs.com/product/glp-2-tirz-714
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2022, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short amino-acid chains held together by peptide bonds. A modified peptide can activate receptors involved in how the body handles meals. Tirzepatide activates GIP and GLP-1 receptors. In “GLP-2 TIRZ,” the GLP-2 wording is a catalog identifier. The SURMOUNT-MAINTAIN trial examined what happened to body weight after adults had already taken tirzepatide during an initial weight-loss phase. [1, 2]

The trial had two periods. In the first, everyone who entered the treatment period received tirzepatide. After 60 weeks, 378 participants were randomized to continue the same assigned intensity, receive a lower study strength, or switch to placebo for another 52 weeks. The three-way comparison addressed maintenance in people who reached randomization after the initial period. The result describes that group. People who stopped during the initial period or never entered it were not part of the randomized maintenance comparison. [1]

At week 112, estimated average weight was 21.9% below the original baseline in the group that continued at the prior intensity, 16.6% below baseline in the lower-strength group, and 9.9% below baseline in the group that switched to placebo. The numbers refer to the beginning of the whole study. They are not percentages lost after week 60. Measuring from the original baseline allowed investigators to see how much of the initial reduction remained by the end of follow-up. [1]

The protocol also allowed people with substantial regain during maintenance to receive a rescue intervention under defined conditions. The main analysis included randomized participants and used prespecified assumptions to handle rescue treatment. Those decisions affect what the final estimates represent. It is useful to keep the entire sequence of the study in mind before comparing its results with a trial where participants were assigned to a treatment at the outset. [1]

The findings separate initial weight change from its maintenance in the same research program. The study provides evidence about the tested assignments and duration. It does not determine a future weight trajectory for any individual or establish what would happen after a longer follow-up. The different average results show why maintenance is a question that calls for its own comparison and measurements. [1]

## Sources

1. Deborah B. Horn et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet (publication 2026-05-12). <https://pubmed.ncbi.nlm.nih.gov/42119587/>
2. Bingfa Sun et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proceedings of the National Academy of Sciences (publication 2022-03-25). <https://pubmed.ncbi.nlm.nih.gov/35333651/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 033 - GLP-2 TIRZ and Glutathione.docx; article 161; content SHA-256 dac72d879a6e8c5dbb16305b997a999affa5fb1f72330efd45be42f3fd80bb27.
